ConvaTec CMD Boosts Growth Outlook, Shares Rise 3%

ConvaTec shares rose over 3% after its Capital Markets Day disclosed upgraded mid‑term organic growth target of 6‑8% and higher divisional forecasts.
Management reaffirmed a 24‑26% margin target, expecting the lower 24% bound to be achieved by 2027.
Division targets raised: Ostomy and Continence Care to single digits, Advanced Wound Care high single digits (2028‑30), Infusion Care to double‑digit growth.
Bank of America analysts kept a Buy rating and 295‑pence target, citing Flexi‑Seal Air and a European Tanabe rollout in 2H26.